These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16167137)

  • 21. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
    Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Swarming and pathogenicity of Proteus mirabilis in the urinary tract.
    Mobley HL; Belas R
    Trends Microbiol; 1995 Jul; 3(7):280-4. PubMed ID: 7551643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Epidemiology of the urinary tract infection in patients with prolonged catheterization in an intensive care unit].
    Kolb R; Rotter M
    Anaesthesist; 1973 May; 22(5):239-42. PubMed ID: 4198502
    [No Abstract]   [Full Text] [Related]  

  • 24. Genotyping demonstrates that the strains of Proteus mirabilis from bladder stones and catheter encrustations of patients undergoing long-term bladder catheterization are identical.
    Sabbuba NA; Stickler DJ; Mahenthiralingam E; Painter DJ; Parkin J; Feneley RC
    J Urol; 2004 May; 171(5):1925-8. PubMed ID: 15076313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New variant Salmonella genomic island 1-U in Proteus mirabilis clinical and food isolates from South China.
    Bi S; Yan H; Chen M; Zhang Z; Shi L; Wang H
    J Antimicrob Chemother; 2011 May; 66(5):1178-9. PubMed ID: 21393148
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activities against biofilm formed by Proteus mirabilis isolates from wound and urinary tract infections.
    Wasfi R; Abd El-Rahman OA; Mansour LE; Hanora AS; Hashem AM; Ashour MS
    Indian J Med Microbiol; 2012; 30(1):76-80. PubMed ID: 22361765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The type III secretion system of Proteus mirabilis HI4320 does not contribute to virulence in the mouse model of ascending urinary tract infection.
    Pearson MM; Mobley HLT
    J Med Microbiol; 2007 Oct; 56(Pt 10):1277-1283. PubMed ID: 17893161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rare visual side effect of urinary tract infection in a patient with a suprapubic catheter.
    Peters P; Merlo J; Boon B; Parker B; Munckhof W
    Br J Hosp Med (Lond); 2012 Jan; 73(1):51. PubMed ID: 22241413
    [No Abstract]   [Full Text] [Related]  

  • 30. Survey of multidrug resistance integrative mobilizable elements SGI1 and PGI1 in Proteus mirabilis in humans and dogs in France, 2010-13.
    Schultz E; Haenni M; Mereghetti L; Siebor E; Neuwirth C; Madec JY; Cloeckaert A; Doublet B
    J Antimicrob Chemother; 2015 Sep; 70(9):2543-6. PubMed ID: 26066582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virulence factors in Proteus bacteria from biofilm communities of catheter-associated urinary tract infections.
    Hola V; Peroutkova T; Ruzicka F
    FEMS Immunol Med Microbiol; 2012 Jul; 65(2):343-9. PubMed ID: 22533980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccines for Proteus mirabilis in urinary tract infection.
    Li X; Mobley HL
    Int J Antimicrob Agents; 2002 Jun; 19(6):461-5. PubMed ID: 12135833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple renal abscesses due to Proteus mirabilis.
    Kakuchi Y
    Clin Exp Nephrol; 2021 Mar; 25(3):322-323. PubMed ID: 33070221
    [No Abstract]   [Full Text] [Related]  

  • 34. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
    Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
    Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and characterisation of dog uropathogenic Proteus mirabilis strains.
    Gaastra W; van Oosterom RA; Pieters EW; Bergmans HE; van Dijk L; Agnes A; ter Huurne HM
    Vet Microbiol; 1996 Jan; 48(1-2):57-71. PubMed ID: 8701578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary pathogenicity of Proteus mirabilis strains isolated from faeces or urine.
    Peerbooms PG; Verweij AM; Oe PL; MacLaren DM
    Antonie Van Leeuwenhoek; 1986; 52(1):53-62. PubMed ID: 3524444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The special affinity of particular types of Proteus mirabilis for the urinary tract.
    Senior BW
    J Med Microbiol; 1979 Feb; 12(1):1-8. PubMed ID: 372530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purple like a glove.
    Eilertson B
    J Hosp Med; 2008 Sep; 3(5):430. PubMed ID: 18951389
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical significance of
    Decôme M; Cuq B; Fairbrother JH; Gatel L; Conversy B
    Can J Vet Res; 2020 Oct; 84(4):252-258. PubMed ID: 33012973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic diversity in Proteus mirabilis isolates found in the urinary tract of rheumatoid arthritis patients.
    Whiteford JR; Wilson C; Tiwana H; Ebringer A
    J Infect; 2000 Nov; 41(3):245-8. PubMed ID: 11120612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.